Sodium enoxaparin and venovenous hemofiltration in treating sudden sensorineural hearing loss and tinnitus.
Sudden sensorineural hearing loss (SSNHL) constitutes a considerable diagnostic challenge because it may be caused by many diverse conditions that may be difficult to recognize. No definitive treatment for SSNHL is universally accepted; the goal of this study was to evaluate the efficacy of sodium enoxaparin associated with venovenous hemofiltration in a therapeutic regimen. We treated 20 patients divided randomly into two numerically equal groups (A and B). Group A patients underwent this therapeutic protocol: Hemofiltration was performed at the first and last day of the protocol while, beginning on the second day of the protocol, sodium enoxaparin was administered subcutaneously at a dose of 4,000 IU once a day for 10 days. After the first hemofiltration, all the patients with complete auditory recovery were discharged without receiving the treatment with sodium enoxaparin. Group B patients received conventional therapy (cortisone, vasoactive agents, and vitamin complexes) administered in physiological solution intravenously twice daily for 10 days. In our randomized, controlled trial, treated patients in group A showed more improvement than did those in group B.
Mora
Renzo
R
Ear, Nose, and Throat Department, University of Genoa, Genoa, Italy. renzomora@libero.it
Dellepiane
Massimo
M
Mora
Francesco
F
Jankowska
Barbara
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000628:therapy*; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000628:therapy*; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D014012:Tinnitus / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin